Cracking the Immune Fingerprint of Metal-organic Frameworks

Overview

Journal Chem Sci

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2022 Feb 25

PMID 35211258

Authors

T Hidalgo

R Simon-Vazquez

A Gonzalez-Fernandez

P Horcajada

Affiliations

Soon will be listed here.

Abstract

The human body is in a never-ending chess game against pathogens. When the immune system, our natural defence tool, is weakened, these organisms are able to escape, overcoming the body's contingency plan, which results in the body going into a pathological state. To overcome this checkmate status, emerging nanomedicines have been successfully employed as one of the best tactics for boosting the immune response, manipulating the body's defence tools for the specific recognition/elimination of pathological cells the active ingredient delivery. However, the vast majority of these drug-delivery systems (DDS) are considered to be exclusively passive vehicles, with nanoscale metal-organic frameworks (nanoMOFs) attracting a great deal of attention due to their versatility and ability to carry and deliver exceptional drug payloads and to modulate their biological bypass. Nonetheless, their intrinsic immunogenicity character has been never addressed. Considering the immense possibilities that nanoMOFs offer as a treatment platform, the present study aimed to unveil the immunological fingerprint of MOFs, including an in-deep evaluation of the cellular oxidation balance, the inflammation and recruitment of immune cells and the precise Th1/Th2 cytokine profile that is triggered. This study aims to gain insights that will make more feasible the design of customized immune-active MOF nanoplatforms according to targeted diseases, as the next ace up immune system sleeve.

Citing Articles

Biomedical Metal-Organic Framework Materials: Perspectives and Challenges.

Wang A, Walden M, Ettlinger R, Kiessling F, Gassensmith J, Lammers T Adv Funct Mater. 2024; 34(43).

PMID: 39726715 PMC: 7617264. DOI: 10.1002/adfm.202308589.

Current status and prospects of MOFs loaded with HO-related substances for ferroptosis therapy.

Deng Y, Huang S, Jiang G, Zhou L, Nezamzadeh-Ejhieh A, Liu J RSC Med Chem. 2024; 15(9):2996-3016.

PMID: 39309362 PMC: 11411616. DOI: 10.1039/d4md00261j.

Mitigating Metal-Organic Framework (MOF) Toxicity for Biomedical Applications.

Wisniewska P, Haponiuk J, Saeb M, Rabiee N, Bencherif S Chem Eng J. 2024; 471.

PMID: 39280062 PMC: 11394873. DOI: 10.1016/j.cej.2023.144400.

Biomimetic functionalized metal organic frameworks as multifunctional agents: Paving the way for cancer vaccine advances.

Tousian B, Khosravi A, Ghasemi M, Kadkhodaie M Mater Today Bio. 2024; 27:101134.

PMID: 39027676 PMC: 11255118. DOI: 10.1016/j.mtbio.2024.101134.

Metal-Organic Frameworks: Unconventional Nanoweapons against COVID.

Alvarez-Miguel I, Fodor B, Lopez G, Biglione C, Svensson Grape E, Ken Inge A ACS Appl Mater Interfaces. 2024; 16(25):32118-32127.

PMID: 38862123 PMC: 11212624. DOI: 10.1021/acsami.4c06174.

References

Sang W, Zhang Z, Dai Y, Chen X . Recent advances in nanomaterial-based synergistic combination cancer immunotherapy. Chem Soc Rev. 2019; 48(14):3771-3810. DOI: 10.1039/c8cs00896e. View

Szebeni J, Simberg D, Gonzalez-Fernandez A, Barenholz Y, Dobrovolskaia M . Roadmap and strategy for overcoming infusion reactions to nanomedicines. Nat Nanotechnol. 2018; 13(12):1100-1108. PMC: 6320688. DOI: 10.1038/s41565-018-0273-1. View

Yang B, Chen Y, Shi J . Reactive Oxygen Species (ROS)-Based Nanomedicine. Chem Rev. 2019; 119(8):4881-4985. DOI: 10.1021/acs.chemrev.8b00626. View

Arora S, Rajwade J, Paknikar K . Nanotoxicology and in vitro studies: the need of the hour. Toxicol Appl Pharmacol. 2011; 258(2):151-65. DOI: 10.1016/j.taap.2011.11.010. View

Bellido E, Guillevic M, Hidalgo T, Santander-Ortega M, Serre C, Horcajada P . Understanding the colloidal stability of the mesoporous MIL-100(Fe) nanoparticles in physiological media. Langmuir. 2014; 30(20):5911-20. DOI: 10.1021/la5012555. View

Mitragotri S, Burke P, Langer R . Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014; 13(9):655-72. PMC: 4455970. DOI: 10.1038/nrd4363. View

Papaioannou N, Beniata O, Vitsos P, Tsitsilonis O, Samara P . Harnessing the immune system to improve cancer therapy. Ann Transl Med. 2016; 4(14):261. PMC: 4971375. DOI: 10.21037/atm.2016.04.01. View

Peleteiro M, Presas E, Gonzalez-Aramundiz J, Sanchez-Correa B, Simon-Vazquez R, Csaba N . Polymeric Nanocapsules for Vaccine Delivery: Influence of the Polymeric Shell on the Interaction With the Immune System. Front Immunol. 2018; 9:791. PMC: 5916973. DOI: 10.3389/fimmu.2018.00791. View

DAmico C, Fontana F, Cheng R, Santos H . Development of vaccine formulations: past, present, and future. Drug Deliv Transl Res. 2021; 11(2):353-372. PMC: 7889058. DOI: 10.1007/s13346-021-00924-7. View

10.

Hidalgo T, Gimenez-Marques M, Bellido E, Avila J, Asensio M, Salles F . Chitosan-coated mesoporous MIL-100(Fe) nanoparticles as improved bio-compatible oral nanocarriers. Sci Rep. 2017; 7:43099. PMC: 5335263. DOI: 10.1038/srep43099. View

11.

Ferrer M, Sureda A, Mestre A, Tur J, Pons A . The double edge of reactive oxygen species as damaging and signaling molecules in HL60 cell culture. Cell Physiol Biochem. 2010; 25(2-3):241-52. DOI: 10.1159/000276558. View

12.

Ruiperez F, Mujika J, Ugalde J, Exley C, Lopez X . Pro-oxidant activity of aluminum: promoting the Fenton reaction by reducing Fe(III) to Fe(II). J Inorg Biochem. 2012; 117:118-23. DOI: 10.1016/j.jinorgbio.2012.09.008. View

13.

Exley C . The pro-oxidant activity of aluminum. Free Radic Biol Med. 2004; 36(3):380-7. DOI: 10.1016/j.freeradbiomed.2003.11.017. View

14.

Naran K, Nundalall T, Chetty S, Barth S . Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases. Front Microbiol. 2019; 9:3158. PMC: 6308495. DOI: 10.3389/fmicb.2018.03158. View

15.

Tamames-Tabar C, Cunha D, Imbuluzqueta E, Ragon F, Serre C, Blanco-Prieto M . Cytotoxicity of nanoscaled metal-organic frameworks. J Mater Chem B. 2020; 2(3):262-271. DOI: 10.1039/c3tb20832j. View

16.

Netea M, Schlitzer A, Placek K, Joosten L, Schultze J . Innate and Adaptive Immune Memory: an Evolutionary Continuum in the Host's Response to Pathogens. Cell Host Microbe. 2019; 25(1):13-26. DOI: 10.1016/j.chom.2018.12.006. View

17.

Wuttke S, Lismont M, Escudero A, Rungtaweevoranit B, Parak W . Positioning metal-organic framework nanoparticles within the context of drug delivery - A comparison with mesoporous silica nanoparticles and dendrimers. Biomaterials. 2017; 123:172-183. DOI: 10.1016/j.biomaterials.2017.01.025. View

18.

Wlaschek M, Singh K, Sindrilaru A, Crisan D, Scharffetter-Kochanek K . Iron and iron-dependent reactive oxygen species in the regulation of macrophages and fibroblasts in non-healing chronic wounds. Free Radic Biol Med. 2018; 133:262-275. DOI: 10.1016/j.freeradbiomed.2018.09.036. View

19.

Prasad A . Zinc: role in immunity, oxidative stress and chronic inflammation. Curr Opin Clin Nutr Metab Care. 2009; 12(6):646-52. DOI: 10.1097/MCO.0b013e3283312956. View

20.

Guevara M, Persano F, Persano S . Nano-immunotherapy: Overcoming tumour immune evasion. Semin Cancer Biol. 2019; 69:238-248. DOI: 10.1016/j.semcancer.2019.11.010. View